利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.024 秒)

    Abusable substance dosage form having reduced abuse potential
    2.
    发明授权
    Abusable substance dosage form having reduced abuse potential 失效
    可吸收的物质剂量形式具有减少的吸收潜力

    公开(公告)号：US5236714A

    公开(公告)日：1993-08-17

    申请号：US265738

    申请日：1988-11-01

    申请人： Eun S. Lee ,  Victor Goetz

    发明人： Eun S. Lee ,  Victor Goetz

    IPC分类号： A61K9/00 ,  A61K9/70 ,  A61K31/445 ,  A61K31/485 ,  A61K45/06 ,  A61K47/06 ,  A61P25/30

    CPC分类号： B09B3/0075 ,  A61K31/445 ,  A61K31/485 ,  A61K9/0004 ,  A61K9/7084 ,  B09B2220/14

    摘要： Compositions and dosage forms for administering abusable substances are disclosed which have a reduced potential for abuse without diminishing the therapeutic or beneficial effects of the abusable substance. Topical compositions for application to the skin or mucosa contain the abusable substance in a form which is permeable to the skin or mucosa to which it is to be applied and an antagonist for the abusable substance is present in the composition in an abuse negating amount and in a form that is impermeable to the skin or mucosa to which the composition is to be applied. Controlled release dosage forms which release the abusable substance from a drug reservoir composition confined behind a release rate controlling barrier have the abusable substance and its antagonist in the drug reservoir. The abusable substance is present in a form that is releasable from the dosage form and the antagonist is present in an abuse negating amount in a form that is not releasable from the dosage form. Thus the compositions and dosage forms of this invention permit the therapeutic use, at substantially full potency, of an abusable substance when use as prescribed but reduce the abuse potential of the compositions and dosage forms by other routes of administration. Preferred embodiments of the invention utilize fentanyl as the abusable substance and naltrexone as the antagonist in a transdermal dosage form.

    摘要翻译： 公开了用于施用可滥用物质的组合物和剂型，其具有降低的滥用可能性，而不会降低可滥用物质的治疗或有益效果。 适用于皮肤或粘膜的局部组合物含有对其要施用的皮肤或粘膜可渗透的形式的可滥用物质，并且可滥用物质的拮抗剂以滥用消除量存在于组合物中 对于要施用组合物的皮肤或粘膜不透水的形式。 从限制在释放速率控制屏障之后的药物储库组合物释放可滥用物质的控制释放剂型在药物储库中具有可滥用物质及其拮抗剂。 可滥用物质以可从剂型释放的形式存在，并且拮抗剂以不能从剂型释放的形式以滥用消除量存在。 因此，当按照规定使用时，本发明的组合物和剂型允许基本上全部效力治疗可使用的物质，但是通过其它给药途径降低组合物和剂型的滥用潜力。 本发明的优选实施方案以透皮剂量形式使用芬太尼作为可滥用物质和纳曲酮作为拮抗剂。

    Human papillomavirus multiplexed assay
    3.
    发明申请
    Human papillomavirus multiplexed assay 失效
    人乳头状瘤病毒多重测定

    公开(公告)号：US20050147961A1

    公开(公告)日：2005-07-07

    申请号：US10513088

    申请日：2003-04-25

    申请人： Mark Esser ,  David Opalka ,  Victor Goetz ,  James Drummond ,  Michael Washabaugh

    发明人： Mark Esser ,  David Opalka ,  Victor Goetz ,  James Drummond ,  Michael Washabaugh

    IPC分类号： G01N33/53 ,  G01N33/543 ,  G01N33/569 ,  C12Q1/70 ,  C07K16/46

    CPC分类号： G01N33/56983 ,  G01N33/54333 ,  G01N2333/025

    摘要： The present invention relates to an immunoassay for simultaneously measuring the presence of antibodies to a plurlity of HPV types that utilizes particle-based flow cytometric analysis. The presence and/or titre of neutralizing antibodies in a test sample are determined in a competitive format, where known, type-specific, fluorescently labeled neutralizing monoclonal antibodies compete with antibodies within a test sample for binding to conformationally sensitive, neutralizing epitopes on specific HPV-VLPs. The invention also provides a microsphere complex comprising a microsphere coupled to an HPV VLP.

    摘要翻译： 本发明涉及用于同时测量使用基于粒子的流式细胞术分析的多种HPV类型的抗体的存在的免疫测定。 以竞争形式确定测试样品中的中和抗体的存在和/或滴度，其中已知的特异性，荧光标记的中和单克隆抗体与测试样品内的抗体竞争结合特异性HPV上的构象敏感的中和表位 -VLPs。 本发明还提供了包含与HPV VLP偶联的微球的微球复合物。

    Human papillomavirus multiplexed assay
    5.
    发明授权
    Human papillomavirus multiplexed assay 失效
    人乳头状瘤病毒多重测定

    公开(公告)号：US07067258B2

    公开(公告)日：2006-06-27

    申请号：US10513088

    申请日：2003-04-25

    申请人： Mark T. Esser ,  David W. Opalka ,  Victor Goetz ,  James E. Drummond ,  Michael W. Washabaugh

    发明人： Mark T. Esser ,  David W. Opalka ,  Victor Goetz ,  James E. Drummond ,  Michael W. Washabaugh

    IPC分类号： C12Q1/68

    CPC分类号： G01N33/56983 ,  G01N33/54333 ,  G01N2333/025

    摘要： The present invention relates to an immunoassay for simultaneously measuring the presence of antibodies to a plurality of HPV types that utilizes particle-based flow cytometric analysis. The presence and/or titre of neutralizing antibodies in a test sample are determined in a competitive format, where known, type-specific, fluorescently labeled neutralizing monoclonal antibodies compete with antibodies within a test sample for binding to conformationally sensitive, neutralizing epitopes on specific HPV-VLPs. The invention also provides a microsphere complex comprising a microsphere coupled to an HPV VLP.

    摘要翻译： 本发明涉及用于同时测量利用基于粒子的流式细胞术分析的多种HPV类型的抗体的存在的免疫测定。 以竞争形式确定测试样品中的中和抗体的存在和/或滴度，其中已知的特异性，荧光标记的中和单克隆抗体与测试样品内的抗体竞争结合特异性HPV上的构象敏感的中和表位 -VLPs。 本发明还提供了包含与HPV VLP偶联的微球的微球复合物。